472
Views
6
CrossRef citations to date
0
Altmetric
Letters to the Editor

Ibrutinib therapy is effective in B-cell prolymphocytic leukemia exhibiting MYC aberrations

, &
Pages 739-742 | Received 01 May 2017, Accepted 20 Jun 2017, Published online: 11 Jul 2017

References

  • Ravandi F, O’Brien S. Chronic lymphoid leukemias other than chronic lymphocytic leukemia: diagnosis and treatment. Mayo Clin Proc. 2005;80:1660–1674.
  • Flatley E, Chen AI, Zhao X, et al. Aberrations of MYC are a common event in B-cell prolymphocytic leukemia. Am J Clin Pathol. 2014;142:347–354.
  • Lens D, De Schouwer PJ, Hamoudi RA, et al. p53 abnormalities in B-cell prolymphocytic leukemia. Blood. 1997;89:2015–2023.
  • Sole F, Woessner S, Espinet B, et al. Cytogenetic abnormalities in three patients with B-cell prolymphocytic leukemia. Cancer Genet Cytogenet. 1998;103:43–45.
  • McCune SL, Gockerman JP, Moore JO, et al. Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia. Leuk Lymphoma. 2002;43:1007–1011.
  • Dearden C. How I treat prolymphocytic leukemia. Blood. 2012;120:538–551.
  • Schlette E, Lai R, Onciu M, et al. Leukemic mantle cell lymphoma: clinical and pathologic spectrum of twenty-three cases. Mod Pathol. 2001;14:1133–1140.
  • Dang CV, O’Donnell KA, Zeller KI, et al. The c-Myc target gene network. Semin Cancer Biol. 2006;16:253–264.
  • Crisostomo RH, Fernandez JA, Caceres W. Complex karyotype including chromosomal translocation (8;14) (q24;q32) in one case with B-cell prolymphocytic leukemia. Leuk Res. 2007;31:699–701.
  • Iioka F, Akasaka T, Hayashida M, et al. B-cell prolymphocytic leukemia carrying t(8;14)(q24;q32), associated with both autoimmune hemolytic anemia and pure red cell aplasia. J Clin Exp Hematopathol. 2014;54:219–224.
  • Put N, Van Roosbroeck K, Konings P, et al. Chronic lymphocytic leukemia and prolymphocytic leukemia with MYC translocations: a subgroup with an aggressive disease course. Ann Hematol. 2012;91:863–873.
  • Woyach JA, Smucker K, Smith LL, et al. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood. 2014;123:1810–1817.
  • Gordon MJ, Raess PW, Young K, et al. Ibrutinib is an effective treatment for B-cell prolymphocytic leukaemia. Br J Haematol. 2016[July 8]. [Epub ahead of print]. doi: 10.1111/bjh.14224.
  • Lenoir GM, Preud’homme JL, Bernheim A, et al. Correlation between immunoglobulin light chain expression and variant translocation in Burkitt’s lymphoma. Nature. 1982;298:474–476.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.